Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression?  NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT.  Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. Listen now! 

Be sure to listen to Episode 8: PRRT (Part One) with Administrative Nurse Lindy Gardner of UCLA Health. 

For more information, visit LACNETS.org.